TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Objective Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion to PV2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interbody Fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Urinary Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Allograft Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With at Least One Biopsy Proven Acute Rejection Episode
Endpoint domain: Mortality/survival
Primary endpoint: Graft Loss
Endpoint domain: Mortality/survival
Primary endpoint: Death Within the First Three Months Post-transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Percent Change From Baseline in Hepatic Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Experiencing One or More Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Acute grade 3+ adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of time within serum AT level target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Themes Generated by Participants Regarding Usage of the Devices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hamilton Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lorazepam Pharmacokinetics (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum bactericidal titers against meningococcal serogroups A & C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-PRP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HBs concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-diphtheria concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-tetanus concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-BPT concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference of IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effort Expenditure for Rewards Task (EEfRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monetary Incentive Delay (MID) Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probabilistic Reward Task (PRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady State Tacrolimus Trough Levels (C24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady State Tacrolimus Exposure (AUC 0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Ty800 oral typhoid vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic exposure to B17MP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-progression rate after 6 cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale (VAS) for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diversity of the intestinal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Plasma HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with One or More Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory-confirmed influenza infection
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory-confirmed non-influenza infection
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Truelove/Witts activity index for disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life, as assessed by Inflammatory Bowel Disease Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: % Growth Inhibition of treated versus untreated cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of Chong Kun Dang Tamsulosin HCl Tablet and Harnal-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Chong Kun Dang Tamsulosin HCl Tablet and Harnal-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of binimetinib in combination with docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reflected Pulse Wave Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Conduit artery endothelium-dependent dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of DFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albumin Excretion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Any Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With AEs Classified by the Indicated Maximum Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shear-Wave Elastography (SWE) Values in kiloPascals (kPa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day weaning success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited Local and Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Unsolicited Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum immunoglobulin G (IgG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of significant hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Mode of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of advance directive
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in necrotic mass ratio (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-drinking Metabolic Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Baseline Metabolic Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of clinically improved inpatients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Response Rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Matsuda composite index of insulin sensitivity (MISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Intensity of Breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: closure time on PFA-100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale (VAS) of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events and Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of residual tumor types RCB-0 and RCB-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Suicidality via Columbia-Suicide Severity Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reported Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Systolic/Diastolic blood pressure from screening to end of study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of diaphragmatic hemiparesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Formation of urinary metabotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Function and quality of life on DASH scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of success block defined as complete motor and sensory block on C5-C6 territories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of hemidiaphragmatic paresis, assessed with the ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ROC AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Require Dose Delay/Reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes Stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diabetes Medication Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of spontaneous resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of molars with clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of molars with radiographic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior chamber reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Frequency, severity, and timing of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemical progression-free survival (bPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Mean improvement in activity limitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Device adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Outcome Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of pomalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath Alcohol Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-Administered Posttraumatic Stress Disorder Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of rotavirus gastroenteritis among all acute gastroenteritis hospitalisations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of rotavirus gastroenteritis among all acute gastroenteritis emergency room visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of medical care associated rotavirus gastroenteritis among all hospitalised children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total score of patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Global Deficit Score From Expanded MATRICS Consensus Cognitive Battery (MCCB)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in UCSD Performance-Based Skills Assessment-Brief (UPSA-B)
Endpoint domain: Life impact
Endpoint subdomain: Functional status
Primary endpoint: Post ERCP Pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Haemostatic Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung cancer detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Body Albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in 17-item HAM-D total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 400-M walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Leg Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days until a dry wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount and character of wound drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With HIV-1 RNA Viral Load ≤ 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: tissue incorporation into ProFlor in the short term postop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue incorporation into ProFlor in the mid term postop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue incorporation into ProFlor in the long term postop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children achieving at least 5x10e6 CD34 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of allogeneic bone marrow transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean acute Serious Bacterial Infection (SBI) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: complete removal rate of colon polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intra-user concordance in assessment of hematuria score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late post-illumination pupillary response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Exercise Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total NNAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The ratio of total NNAL-gluc to NNAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The urinary DNA adducts of 3-mA upon TNE correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in adherence to prescribed cardiology medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative incidence of pulmonary atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change in Snoring Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inattention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Social problem-solving inventory - patient report
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Social problem-solving inventory - caregiver report
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety of vemurafenib administration
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of mother to child transmission of HIV
Endpoint domain: Mortality/survival
Primary endpoint: Absolute change in ongoing calcium deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy and response time at an explicit emotional evaluation task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy and response time at a semantic categorization task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GB volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLE100 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Surgeon preference for neuromuscular blocking agents
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postprandial blood sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Plasma Concentration of CF102 (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiogram signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Body position signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of PEDF, VEGF, HIF-1 alpha, MMP-2, -8 and -9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: histomorphological classification of the plaque based on AHA classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ultrasonographic data - grey scale median (GSM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of lenalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WOMAC Pain Subscale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of follicles >15 mm at day of ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Glucocorticoid Toxicity Score
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in carotid IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of adverse events per participant
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in Comfort behavioral scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MATRICS Consensus Cognitive Battery (MCCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: University of California Performance-based Skills Assessment (UPSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brief Assessment of Cognition in Schizophrenia (BACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Scale for the Assessment of Negative Symptoms (SANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor and Sensory Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects following Modified Atkins Diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with ketosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Area Under the Concentration-Time Curve From 0 to 24 Hours of Valganciclovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events Leading to Dose Interruption or Modification
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Opportunistic Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative frequency of recurrence of colorectal adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Subjective appetite
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Food intake at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with certain etiologic diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of Perceived exertion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression Free Survival at 4 Months
Endpoint domain: Mortality/survival
Primary endpoint: incidence of CDI
Endpoint domain: Adverse events/effects
Primary endpoint: Change in disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repetitions Completed for Each Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Complete Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Smoothness Per Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in abdominal circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: estimated fetal weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Receipt of immunizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes